Dai­ichi Sankyo set­tles its car­dio drug law­suit with Es­pe­ri­on, which will get $125M mile­stone pay­ment

Dai­ichi Sankyo Eu­rope and Es­pe­ri­on Ther­a­peu­tics have agreed to a $125 mil­lion change to their col­lab­o­ra­tion agree­ment, set­tling a le­gal dis­pute that erupt­ed af­ter the tri­al read­out of the car­dio­vas­cu­lar drug on which they are part­nered.

The com­pa­nies an­nounced Wednes­day that Dai­ichi Sankyo would pay Es­pe­ri­on $100 mil­lion this month ahead of po­ten­tial ap­provals by the Eu­ro­pean Med­i­cines Agency for two car­dio­vas­cu­lar drugs: Nilem­do and Nus­ten­di (mar­ket­ed in the US as Nexle­tol and Nexl­izet, re­spec­tive­ly). Dai­ichi will al­so pay an ad­di­tion­al $25 mil­lion to Es­pe­ri­on in the quar­ter af­ter the EMA’s de­ci­sion on the pend­ing ap­pli­ca­tion for the drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER